沃贡因对排泄输送器BCRP和MRP2的影响,解释了其在性结肠炎中的有效性:对代谢和运输相互作用的影响
Yuanyuan Liu1, Zerong Zhang2, Xiaoyan Li2
1State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Key Laboratory for Translational Cancer Research of Chinese Medicine, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, Guangdong 518000, China.
Pharmacological research
|January 2, 2025
概括
在Wogonin中工作.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 作为一种黄类物质的wogonin显示出治疗性结肠炎 (UC) 的治疗潜力.
- 沃戈宁有效性的确切机制,特别是其生物可用性和运输,需要进一步研究.
- 流体输送体,乳腺癌抗性蛋白 (BCRP) 和多重耐药性相关蛋白2 (MRP2) 是黄类药物的肝内循环的关键.
研究的目的:
- 调查沃贡因对BCRP和MRP2的调节作用.
- 阐明BCRP和MRP2在沃贡因的抗UC治疗作用中的参与.
- 在UC治疗中识别wogonin的新分子标和机制.
主要方法:
- 使用硫酸德克斯 (DSS) 诱导的性结肠炎小鼠模型.
- 使用BCRP和MRP2淘汰赛小鼠 (Bcrp-/- -Mrp2-/-) 和野生类型 (WT) littermates进行比较分析.
- 进行了体外研究和线粒体亚细胞器官的蛋白质组测序.
主要成果:
- 与WT小鼠相比,Wogonin在Bcrp-/- -Mrp2-/-小鼠中的抗UC疗效降低了.
- 缺少BCRP和MRP2导致血沃戈宁度增加和结肠沃戈宁度降低.
- 抑制BCRP和MRP2抑制了Wogonin的细胞和线粒体葡萄糖化代谢,降低了Wogonoside水平.
- 沃戈宁通过抑制线粒体中的阿法胺 (AFM) 来表现出抗UC作用,这是由BCRP和MRP2调节的过程.
结论:
- 在UC中,BCRP和MRP2显著影响沃贡因的处置和治疗疗效.
- 这些流量载体的缺陷会损害沃贡因的结肠传递和抗UC活性.
- 沃贡因通过抑制线粒体亚胺产生抗UC作用,其作用由BCRP和MRP2.2调节.
- 这些发现为wogonin在UC的临床应用提供了新的机制理解和药理基础.
相关概念视频
Carrier-Mediated Transport
247
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
247
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Hepatic Drug Clearance: Role of Transporters
34
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
34
Factors Influencing Drug Absorption: Disease States and Pharmacology
428
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
428
Nonlinear Pharmacokinetics: Role of Transporters
28
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
28
Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110


